View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 46. 1088
Open access

Cross Mark

A hepatocellularis carcinoma (HCC) a halálhoz vezető rosszindulatú daganatos betegségek között a hatodik leggyakoribb megbetegedés a világon. Az esetek döntő részében (80–90%) májcirrhosis talaján alakul ki. A cirrhosis fő oka a krónikus B- és C-vírus-fertőzés, valamint a tartós alkoholfogyasztás. A kóroki tényezők kezelése, megszüntetése csökkenti a HCC kockázatát. A szerzők összefoglalják azokat az irodalmi adatokat, amelyek a modern antivirális kezelés hatását vizsgálják a HCC előfordulására. Megállapítható, hogy az antivirális kezelés (interferon és nukleozidanalóg készítmény) akkor is csökkenti a HCC előfordulási gyakoriságát és a HCC kuratív kezelés utáni kiújulását, amikor az antivirális terápia nem eredményezi a vírus eliminációját. Elősegítheti a HCC kockázatának csökkenését a redox status egyensúlyának biztosítása is.

  • Evans, T., Stein, C. (eds.): The World Health Report 2003. World Health Organisation, Geneva, 2003.

    '', in The World Health Report 2003 , (2003 ) -.

  • Parkin, D. M., Bray, F., Ferlay, J. és mtsa: Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55 , 74–108.

    Ferlay J. , 'Global cancer statistics, 2002 ' (2005 ) 55 CA Cancer J. Clin. : 74 -108.

  • El-Serag, H. B., Rudolph, K. L.: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132 , 2557–2576.

    Rudolph K. L. , 'Hepatocellular carcinoma: epidemiology and molecular carcinogenesis ' (2007 ) 132 Gastroenterology : 2557 -2576.

    • Search Google Scholar
  • Fehér J., Lengyel G. (szerk.): Hepatológia. Medicina Könyvkiadó, Budapest, 2001.

    '', in Hepatológia , (2001 ) -.

  • Schütte, K., Bornschein, J., Malfertheiner, P.: Hepatocellular carcinoma – epidemiological trends and risk factors. Dig. Dis., 2009, 27 , 80–92.

    Malfertheiner P. , 'Hepatocellular carcinoma – epidemiological trends and risk factors ' (2009 ) 27 Dig. Dis. : 80 -92.

    • Search Google Scholar
  • Hassan, M. M., Hwang, L.Y., Hatten, C. J.: Risk factors for hepatocellular carcinoma: Synergis of alcohol with viral hepatitis and diabetes mellitus. Hepatology, 2002, 36 , 1206–1213.

    Hatten C. J. , 'Risk factors for hepatocellular carcinoma: Synergis of alcohol with viral hepatitis and diabetes mellitus ' (2002 ) 36 Hepatology : 1206 -1213.

    • Search Google Scholar
  • Hagymási K., Tulassay Zs.: Az elsődleges májrák epidemiológiája, kóroka és kialakulásának molekuláris háttere. Orv. Hetil., 2008, 149 , 541–548.

    Tulassay Zs. , 'Az elsődleges májrák epidemiológiája, kóroka és kialakulásának molekuláris háttere ' (2008 ) 149 Orv. Hetil. : 541 -548.

    • Search Google Scholar
  • Al-Nozha, O. M., Ashgar, H. A., Kahn, M. és mtsa: Hepatocellular carcinoma in the abscence of liver cirrhosis in a treated hepatitis C virus patient. Ann. Saudi Med. J., 2009, 29 , 235–236.

    Kahn M. , 'Hepatocellular carcinoma in the abscence of liver cirrhosis in a treated hepatitis C virus patient ' (2009 ) 29 Ann. Saudi Med. J. : 235 -236.

    • Search Google Scholar
  • Baffis, V., Shrier, I., Sherker, A. H. és mtsa: Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann. Intern. Med., 1999, 131 , 696–701.

    Sherker A. H. , 'Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection ' (1999 ) 131 Ann. Intern. Med. : 696 -701.

    • Search Google Scholar
  • Jeong, S., Aikata, H., Katamura, Y. és mtsai: Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J. Gastroenterol., 2007, 13 , 5188–5195.

    Katamura Y. , 'Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma ' (2007 ) 13 World J. Gastroenterol. : 5188 -5195.

    • Search Google Scholar
  • Jeong, S., Aikata, H., Katamura, Y. és mtsai: Effects of a 24-week course of interferon-α therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J. Gastroenterol., 2007, 13 , 5343–5350.

    Katamura Y. , 'Effects of a 24-week course of interferon-α therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma ' (2007 ) 13 World J. Gastroenterol. : 5343 -5350.

    • Search Google Scholar
  • Ishikawa, T.: Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J. Gastroenterol., 2008, 14 , 6140–6144.

    Ishikawa T. , 'Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients ' (2008 ) 14 World J. Gastroenterol. : 6140 -6144.

    • Search Google Scholar
  • Ikeda, K., Arase, Y., Saitoh, S. és mtsai: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor – A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology, 2000, 32 , 228–232.

    Saitoh S. , 'Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor – A prospective randomized study of hepatitis C virus-related liver cancer ' (2000 ) 32 Hepatology : 228 -232.

    • Search Google Scholar
  • Tarao, K., Takemiya, S., Tamai, S. és mtsai: Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virusassociated cirrhosis and HCC. Cancer, 1997, 79 , 688–694.

    Tamai S. , 'Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virusassociated cirrhosis and HCC ' (1997 ) 79 Cancer : 688 -694.

    • Search Google Scholar
  • Kubo, S., Nishiguchi, S., Hirohashi, K. és mtsai: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann. Intern. Med., 2001, 134 , 963–967.

    Hirohashi K. , 'Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial ' (2001 ) 134 Ann. Intern. Med. : 963 -967.

    • Search Google Scholar
  • Suou, T., Mitsuda, A., Koda, M. és mtsai: Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol. Res., 2001, 20 , 301–311.

    Koda M. , 'Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study ' (2001 ) 20 Hepatol. Res. : 301 -311.

    • Search Google Scholar
  • Shiratori, Y., Shiina, S., Teratani, T. és mtsai: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann. Intern. Med., 2003, 138 , 299–306.

    Teratani T. , 'Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus ' (2003 ) 138 Ann. Intern. Med. : 299 -306.

    • Search Google Scholar
  • Sakaguchi, Y., Kudo, M., Fukunaga, T. és mtsai: Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology, 2005, 48 , 64–70.

    Fukunaga T. , 'Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma ' (2005 ) 48 Intervirology : 64 -70.

    • Search Google Scholar
  • Lodato, F., Mazzella, G., Festi, D. és mtsai: Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J. Gastroenterol., 2006, 12 , 7239–7249.

    Festi D. , 'Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations ' (2006 ) 12 World J. Gastroenterol. : 7239 -7249.

    • Search Google Scholar
  • Lin, C. L., Kao, J. H.: Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J. Biomed. Sci., 2008, 15 , 137–145.

    Kao J. H. , 'Hepatitis B viral factors and clinical outcomes of chronic hepatitis B ' (2008 ) 15 J. Biomed. Sci. : 137 -145.

    • Search Google Scholar
  • Chen, G., Lin, W., Shen, F. és mtsai: Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am. J. Gastroenterol., 2006, 101 , 1797–1803.

    Shen F. , 'Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study ' (2006 ) 101 Am. J. Gastroenterol. : 1797 -1803.

    • Search Google Scholar
  • Bishayee, A., Dhir, N.: Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem-Biol. Interact., 2009, 179 , 131–144.

    Dhir N. , 'Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis ' (2009 ) 179 Chem-Biol. Interact. : 131 -144.

    • Search Google Scholar
  • Seufi, A. M., Ibrahim, S. S., Elmaghraby, T. K. és mtsai: Preventive effect of the flavonoid, quercetin, on hepatic cancer in rats via oxidant/antioxidant activity: molecular and histological evidences. J. Exp. Clin. Cancer Res., 2009, 28 , 80–88.

    Elmaghraby T. K. , 'Preventive effect of the flavonoid, quercetin, on hepatic cancer in rats via oxidant/antioxidant activity: molecular and histological evidences ' (2009 ) 28 J. Exp. Clin. Cancer Res. : 80 -88.

    • Search Google Scholar
  • Feher, J., Lengyel, G.: Silymarin in the treatment of chronic liver diseases: Past and Future. Clin. Exp. Med. J., 2009, 3 , 403–413.

    Lengyel G. , 'Silymarin in the treatment of chronic liver diseases: Past and Future ' (2009 ) 3 Clin. Exp. Med. J. : 403 -413.

    • Search Google Scholar
  • Tarao, K., Fujiyama, S., Ohkawa, S. és mtsai: Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis. Cancer Epidemiol. Biomarkers Prev., 2005, 14 , 164–169.

    Ohkawa S. , 'Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis ' (2005 ) 14 Cancer Epidemiol. Biomarkers Prev. : 164 -169.

    • Search Google Scholar
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 30 27 3
PDF Downloads 54 50 5